Skip to main content

Table 4 Percentage of incidences of adverse events at months 1, 3 and 6 following treatment with erenumab in the overall population of patients treated with erenumab

From: A prospective real-world analysis of erenumab in refractory chronic migraine

 Month 1 (N = 162) N (%)Month 3 (N = 100) N (%)Month 6 (N = 73) N (%)
Constipation32 (20%)11 (11%)4 (5%)
Cold-flu/like25 (15%)8 (8%)2 (3%)
Generalised aches/pain10 (6%)1 (1%)1 (1%)
Itchiness8 (5%)1 (1%)1 (1%)
Injection site reaction (pain/skin redness)5 (3%)0 (0%)1 (1%)
Muscle spasms3 (2%)0 (0%)0 (0%)
Others15 (9%)4 (4%)3 (4%)
  1. N, number
\